

Next Edge Biotech and Life Sciences Opportunities Fund
 Quarterly Summary of Investment Portfolio as at September 30, 2024



Portfolio by Asset Mix	% of Net Asset Value	
	Long	Short
United States Equity	59.0	-
Foreign Equity	11.1	-
Equity Options	9.6	(0.9)
Canadian Equity	9.0	-
United States Bond	1.8	-
	90.5	(0.9)
Cash and Cash Equivalents	10.7	-
Other Net Assets (Liabilities)	(0.3)	-
	100.9	(0.9)

Portfolio by Sector	% of Net Asset Value	
	Long	Short
Pharmaceuticals, Biotechnology & Life Sciences	69.7	-
Health Care Equipment & Services	11.2	-
Equity Options	9.6	(0.9)
	90.5	(0.9)
Cash and Cash Equivalents	10.7	-
Other Net Assets (Liabilities)	(0.3)	-
	100.9	(0.9)

Portfolio by Geography	% of Net Asset Value	
	Long	Short
United States	70.4	(0.9)
International	11.1	-
Canada	9.0	-
	90.5	(0.9)
Cash and Cash Equivalents	10.7	-
Other Net Assets (Liabilities)	(0.3)	-
	100.9	(0.9)

Next Edge Biotech and Life Sciences Opportunities Fund
 Quarterly Summary of Investment Portfolio as at September 30, 2024



Top 25 Long Positions ¹	% of Net Asset Value
Cash and cash equivalent	10.7
Phathom Pharmaceuticals Inc.	4.4
TG Therapeutics Inc.	4.1
CRISPR Therapeutics AG	3.7
10X Genomics Inc.	3.6
Neuraxis Inc.	3.5
Urogen Pharma Ltd.	3.3
Schrodinger Inc.	3.3
Aurinia Pharmaceuticals Inc.	2.8
Microbix Biosystems Inc.	2.6
Acumen Pharmaceuticals Inc.	2.6
Protalix BioTherapeutics Inc.	2.4
MeiraGTx Holdings PLC	2.4
Ginkgo Bioworks Holdings Inc.	2.3
Unicycive Therapeutics Inc.	2.2
Inari Medical Inc.	2.2
Achieve Life Sciences Inc.	2.2
Inmune Bio Inc.	2.1
Cellectar Biosciences Inc.	2.1
Reviva Pharmaceuticals Holdings Inc.	2.1
Regenxbio Inc.	2.0
Guardant Health Inc.	2.0
Eledon Pharmaceuticals Inc.	2.0
Nektar Therapeutics	1.9
Pacific Biosciences of California Inc.	1.9

Top 6 Short Positions ¹	% of Net Asset Value
SPDR S&P 500 ETF TRUST@510 PUT OPT 31 OCT 24	(0.4)
VIKING THERAPEUTICS INC@90 CALL OPT 15 NOV 24	(0.2)
VIKING THERAPEUTICS INC@95 CALL OPT 15 NOV 24	(0.2)
SPDR S&P 500 ETF TRUST@480 PUT OPT 18 OCT 24	(0.1)
CYTOKINETICS INC@90 CALL OPT 15 NOV 24	-
VIKING THERAPEUTICS INC@95 CALL OPT 18 OCT 24	-

1. The are no other short positions as at September 30, 2024

Net Asset Value of Next Edge Biotech and Life Sciences Opportunities Fund as at September 30, 2024	7,709,725
---	------------------